Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovent Biologics ( (HK:1801) ) has shared an update.
Innovent Biologics, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement underscores the company’s commitment to strong governance and strategic oversight, which may enhance its operational effectiveness and industry positioning.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a company incorporated in the Cayman Islands, operating within the biotechnology industry. The company focuses on developing and manufacturing biologic drugs, primarily targeting cancer and other major diseases, aiming to innovate within the healthcare sector.
Average Trading Volume: 23,906,438
Technical Sentiment Signal: Buy
Current Market Cap: HK$171.2B
For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.